The triple negative subtype of breast cancer (TNBC), devoid of the hormone estrogen/progesterone receptor (ER/PR+) expression and HER2 overexpression (HER2+), is a heterogeneous group of aggressive diseases that account for 15–20 % of all breast cancer cases. This evidence concerns the gene PGR and breast cancer.